Cancer Institute– A national cancer institute
designated cancer center

Janice Brown

Back to Profile

Publication Details

  • Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects.

    Wloch MK, Smith LR, Boutsaboualoy S, Reyes L, Han C, Kehler J, Smith HD, Selk L, Nakamura R, Brown JM, Marbury T, Wald A, Rolland A, Kaslow D, Evans T, Boeckh M. J Infect Dis. 2008; 197 (12): 1634-42

    VCL-CB01, a candidate cytomegalovirus (CMV) DNA vaccine that contains plasmids encoding CMV phosphoprotein 65 (pp65) and glycoprotein B (gB) to induce cellular and humoral immune responses and that is formulated with poloxamer CRL1005 and benzalkonium chloride to enhance immune responses, was evaluated in a phase 1 clinical trial.

    PubMedID: 18444883

Stanford Medicine Resources:

Footer Links: